La discusión conceptual sobre el milenarismo y mesianismo en Latinoamérica

Este artículo fue leído como ponencia en el 50 Congreso del ICA (International Congress of Americanists),"Mensajes universales de las Américas para el siglo XXI", que tuvo lugar en Varsovia del 10-14 de julio de 2000,dentro del Simposio "Movimientos religiosos en las Américas : religiosidad popular o mesianismo"

Statistical and econometric analysis of the treatment of HIV/AIDS

The epidemic of HIV/AIDS in the United States is constantly changing and evolving, starting from patient zero to now an estimated 650,000 to 900,000 Americans infected. The nature and course of HIV changed dramatically with the introduction of antiretrovirals. This discourse examines many different facets of HIV from the beginning where there wasn't any treatment for HIV until the present era of highly active antiretroviral therapy (HAART). By utilizing statistical analysis of clinical data, this paper examines where we were, where we are and projections as to where treatment of HIV/AIDS is headed.

Chapter Two describes the datasets that were used for the analyses. The primary database utilized was collected by myself from an outpatient HIV clinic. The data included dates from 1984 until the present. The second database was from the Multicenter AIDS Cohort Study (MACS) public dataset. The data from the MACS cover the time between 1984 and October 1992. Comparisons are made between both datasets.

Chapter Three discusses where we were. Before the first anti-HIV drugs (called antiretrovirals) were approved, there was no treatment to slow the progression of HIV. The first generation of antiretrovirals, reverse transcriptase inhibitors such as AZT (zidovudine), DDI (didanosine), DDC (zalcitabine), and D4T (stavudine) provided the first treatment for HIV. The first clinical trials showed that these antiretrovirals had a significant impact on increasing patient survival. The trials also showed that patients on these drugs had increased CD4+ T cell counts. Chapter Three examines the distributions of CD4 T cell counts. The results show that the estimated distributions of CD4 T cell counts are distinctly non-Gaussian. Thus distributional assumptions regarding CD4 T cell counts must be taken, into account when performing analyses with this marker. The results also show the estimated CD4 T cell distributions for each disease stage: asymptomatic, symptomatic and AIDS are non-Gaussian. Interestingly, the distribution of CD4 T cell counts for the asymptomatic period is significantly below that of the CD4 T cell distribution for the uninfected population suggesting that even in patients with no outward symptoms of HIV infection, there exists high levels of immunosuppression.

Chapter Four discusses where we are at present. HIV quickly grew resistant to reverse transcriptase inhibitors which were given sequentially as mono or dual therapy. As resistance grew, the positive effects of the reverse transcriptase inhibitors on CD4 T cell counts and survival dissipated. As the old era faded a new era characterized by a new class of drugs and new technology changed the way that we treat HIV-infected patients. Viral load assays were able to quantify the levels of HIV RNA in the blood. By quantifying the viral load, one now had a faster, more direct way to test antiretroviral regimen efficacy. Protease inhibitors, which attacked a different region of HIV than reverse transcriptase inhibitors, when used in combination with other antiretroviral agents were found to dramatically and significantly reduce the HIV RNA levels in the blood. Patients also experienced significant increases in CD4 T cell counts. For the first time in the epidemic, there was hope. It was hypothesized that with HAART, viral levels could be kept so low that the immune system as measured by CD4 T cell counts would be able to recover. If these viral levels could be kept low enough, it would be possible for the immune system to eradicate the virus. The hypothesis of immune reconstitution, that is bringing CD4 T cell counts up to levels seen in uninfected patients, is tested in Chapter Four. It was found that for these patients, there was not enough of a CD4 T cell increase to be consistent with the hypothesis of immune reconstitution.

In Chapter Five, the effectiveness of long-term HAART is analyzed. Survival analysis was conducted on 213 patients on long-term HAART. The primary endpoint was presence of an AIDS defining illness. A high level of clinical failure, or progression to an endpoint, was found.

Chapter Six yields insights into where we are going. New technology such as viral genotypic testing, that looks at the genetic structure of HIV and determines where mutations have occurred, has shown that HIV is capable of producing resistance mutations that confer multiple drug resistance. This section looks at resistance issues and speculates, ceterus parabis, where the state of HIV is going. This section first addresses viral genotype and the correlates of viral load and disease progression. A second analysis looks at patients who have failed their primary attempts at HAART and subsequent salvage therapy. It was found that salvage regimens, efforts to control viral replication through the administration of different combinations of antiretrovirals, were not effective in 90 percent of the population in controlling viral replication. Thus, primary attempts at therapy offer the best change of viral suppression and delay of disease progression. Documentation of transmission of drug-resistant virus suggests that the public health crisis of HIV is far from over. Drug resistant HIV can sustain the epidemic and hamper our efforts to treat HIV infection. The data presented suggest that the decrease in the morbidity and mortality due to HIV/AIDS is transient. Deaths due to HIV will increase and public health officials must prepare for this eventuality unless new treatments become available. These results also underscore the importance of the vaccine effort.

The final chapter looks at the economic issues related to HIV. The direct and indirect costs of treating HIV/AIDS are very high. For the first time in the epidemic, there exists treatment that can actually slow disease progression. The direct costs for HAART are estimated. It is estimated that the direct lifetime costs for treating each HIV infected patient with HAART is between $353,000 to $598,000 depending on how long HAART prolongs life. If one looks at the incremental cost per year of life saved it is only $101,000. This is comparable with the incremental costs per year of life saved from coronary artery bypass surgery.

Policy makers need to be aware that although HAART can delay disease progression, it is not a cure and HIV is not over. The results presented here suggest that the decreases in the morbidity and mortality due to HIV are transient. Policymakers need to be prepared for the eventual increase in AIDS incidence and mortality. Costs associated with HIV/AIDS are also projected to increase. The cost savings seen recently have been from the dramatic decreases in the incidence of AIDS defining opportunistic infections. As patients who have been on HAART the longest start to progress to AIDS, policymakers and insurance companies will find that the cost of treating HIV/AIDS will increase.

The far-field spatial coherence of Gaussian Schell-model beam in turbulence in terms of position vectors

Spatial coherence properties of beam produced by Gaussian Schell-model source when the beam is propagating through atmosphere have been analyzed in terms of position vectors. New expressions for cross-spectral density of optical field and spectral degree of coherence as well as radiant intensity have been developed. Numerical results illustrated in this paper indicate the coherence degradation suffered from atmospheric turbulence and their directional dependence. (C) 2007 Elsevier GmbH. All rights reserved.

Efeito da temperatura de incubação na cinética e no equilíbrio da biossorção do cádmio por Sargassum filipendula

O uso de biomassas para biossorção de metais pesados é bem documentado na literatura e vários tipos de espécies de microrganismos e algas já foram testados. A maior parte destes trabalhos foi realizada com biomassa seca para prevenir qualquer resposta metabólica indesejável. Vários estudos na literatura sugerem o uso de biomassa seca sobre condições moderadas, tais como secagem ao sol; por outro lado, vários trabalhos recomendam a faixa de 313K a 353K para garantir completa inativação da biomassa. O efeito da biomassa seca ao sol a 303K e seca a 333K em estufa na remoção de Cd2+ é aqui reportado. A avaliação dos resultados foi baseada na cinética e capacidade de remoção do metal pela alga Sargassum filipendula. Os resultados indicam que a adsorção máxima de metal não foi notadamente reduzida quando a biomassa seca em estufa foi usada, para concentrações de cádmio na faixa de 10,0 a 500,0 mg L-1. O estudo cinético realizado indicou que o modelo de pseudo segunda ordem ajustou melhor os dados experimentais, tanto para uma solução diluída (10 mg L-1) quanto para a concentrada (100 mg L-1). Em ambos os casos, os efeitos da secagem em estufa, a 60C refletiu-se suavemente na remoção do metal. Os dados experimentais foram melhor ajustados pelo modelo de Langmuir em comparação com o modelo de Freundlich. Análises termogravimétricas mostraram que não havia dano estrutural no biossorvente devido à secagem em estufa. O espectro de infravermelho não indicou diferença entre a biomassa in natura e seca. O efeito da temperatura na biossorção do metal significativo na faixa de 303K a 328K, refletindo-se na capacidade de remoção do cádmio

Prism coupling of ultrashort light pulses into waveguides

We discuss coupling of ultrashort light pulses into waveguides by use of a prism waveguide coupler configuration. Theoretical analysis indicates that an extra loss induced by the short coherence times of ultrashort pulses, which has a strong effect on the reflected light and the optimum coupling condition, appears in the waveguide. Numerical simulations show that the reflectance strongly depends on the coherence times of ultrashort pulses. A method for realizing optimum coupling by compensating for the extra loss is proposed as well in this paper. A preliminary experiment of employing ultrashort pulses with different coherence times was carried out, and good agreement between theory and experiment was obtained. (c) 2006 Optical Society of America.

El voluntariado y las ONG, en España y Puerto Rico; su necesidad de una regulación jurídica plena

353 p.

El deseo nacional : la gramática del surgimiento de los sujetos nacionales

353 p.

Influence of heat treatment on spectroscopic properties of Er3+ in multicomponent ZrF4-ZnF2-AlF3-YF3-MF2 (M = Ca, Sr, Ba) based glass

Er3+ doped multicomponent fluoride based glass was prepared. These precursor fluoride glass samples were then heated using different schedules. Crystalline phase particles were successfully precipitated in the multicomponent fluoride glass samples after heat treatment. The influence of heat treatment on the spectroscopic properties of Er3+ in multicomponent fluoride based glass samples were discussed. Small changes of the Judd-Ofelt parameters Omega(i) (i = 2,4,6) were found in multicomponent fluoride glass samples before and after heat treatment compared to oxyfluoride telluride glass. Preparation conditions used to produce transparent multicomponent fluoride glass ceramics doped with rare-earth ions are discussed. (c) 2007 Elsevier B.V. All rights reserved.

Efeitos do estradiol sobre a função endotelial, sensibilidade insulínica e viscosidade sanguínea em mulheres na pós-menopausa com excesso de peso

A ação que o estrogênio desempenha sobre o endotélio depende da integridade deste e consequentemente das características clínicas de cada indivíduo. O uso da terapia hormonal da menopausa (THM) em mulheres com baixo risco cardiovascular geralmente resulta em efeitos benéficos, desde que iniciado em um período próximo da menopausa. Em contrapartida, o seu uso em mulheres com alto risco cardiovascular, como diabéticas ou portadoras de lesões ateroscleróticas já estabelecidas, e ainda naquelas com início da THM em um período superior a dez anos da menopausa geralmente resulta em efeitos maléficos. Nosso objetivo é avaliar os efeitos do estrogênio sobre a função endotelial em mulheres com sobrepeso ou obesidade, ou seja, indivíduos com risco cardiovascular intermediário. Para isso, 44 mulheres na pós-menopausa com idade entre 47 a 55 anos e índice de massa corporal (IMC) de 27,5 a 34,9kg/m, foram randomizadas nos grupos placebo (P) e estrogênio transdérmico (ET). A intervenção consistiu no uso transdérmico de estradiol, 1mg por dia, por um período de três meses. As participantes realizaram avaliação da reatividade endotelial em repouso e após isquemia [pletismografia por oclusão venosa (POV), com medidas do fluxo sanguíneo do antebraço (FSA) e videocapilaroscopia dinâmica do leito periungueal (VCLP), com medidas da velocidade de deslocamento das hemácias (VDH)], dosagens de moléculas de adesão [E-selectina, molécula de adesão intercelular (ICAM-1) e molécula de adesão vascular (VCAM-1)], aferição da sensibilidade insulínica [através do homeostatic model assessment of insulin resistance (HOMA-IR) e área sob a curva (AUC) da insulina durante o teste oral de tolerância à glicose (TOTG)] e mensurações das viscosidades sanguínea e plasmática. As participantes apresentaram idade de 51,77 2,3 anos, IMC de 31,52 2,54 kg/m e tempo de menopausa de 3 [2-5] anos. O grupo P não apresentou nenhuma mudança significativa em qualquer variável. Após a intervenção, o grupo ET comparado ao basal apresentou menor tempo para atingir a VDH máxima durante a hiperemia reativa pós-oclusiva (HRPO) após 1 min de isquemia (4,0 [3,25-5,0] vs. 5,0 [4,0-6,0] s, P<0.05) e maior VDH tanto em repouso (0,316 [0,309-0,326] vs. 0,303 [0,285-0,310] mm/s; P<0,001) quanto na HRPO (0,374 [0,353-0,376] vs. 0,341 [0,334-0,373] mm/s; P<0,001), assim como observamos maior FSA em repouso (2,46 [1,81-3,28] vs. 1,89 [1,46-2,44] ml/min.100ml tecido-1; P<0,01) e durante a HRPO após 3 min de isquemia (6,39 [5,37-9,39] vs. 5,23 [4,62-7,47] ml/min.100ml tecido-1; P<0,001). O grupo ET também apresentou diminuição nos níveis solúveis de E-Selectina (68,95 [50,18-102,8] vs. 58,4 [44,53-94,03] ng/ml; P<0,05), de ICAM-1 (188 [145-212] vs. 175 [130-200] ng/ml; P<0,01), do HOMAIR (3,35 1,67 vs. 2,85 1,60; P<0,05) e da AUC da insulina durante o TOTG (152 [117-186] vs. 115 [85-178]; P<0,01), além de diminuição das viscosidades sanguínea com hematócrito nativo (3,72 0,21 vs. 3,57 0,12 mPa.s; P<0,01) e plasmática (1,49 0,10 vs. 1,45 0,08 mPa.s; P<0,05), comparado ao seu basal. Em conclusão o uso de estradiol transdérmico em mulheres com excesso de peso e menopausa recente, promove melhora da função endotelial, além de oferecer proteção a outros fatores de risco cardiovascular.